Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans

Archives of Dermatology

Volumn 145, Issue 7, 2009, Pages 792-796

  Han, Anne ^a,c   Chen, Elbert H ^b   Niedt, George ^c   Sherman, William ^c   Ratner, Désirée ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ARTICLE; CASE REPORT; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FLANK PAIN; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; HYALINE DEGENERATION; NAUSEA; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; DERMATOFIBROSARCOMA; HUMANS; NEOADJUVANT THERAPY; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 67650799353     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.140     Document Type: Article

References (28)

1. Mehrany K, Swanson NA, Heinrich MC, et al. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. Dermatol Surg. 2006;32(3):456-459.
2. Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996; 35(3, pt 1):355-374, quiz 375-376.
3. Mark RJ, Bailet JW, Tran LM, Poen J, Fu YS, Calcaterra TC. Dermatofibrosarcoma protuberans of the head and neck: a report of 16 cases. Arch Otolaryngol Head Neck Surg. 1993;119(8):891-896.
4. Rutgers EJ, Kroon BB, Albus-Lutter CE, Gortzak E. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol. 1992;18(3):241-248.
5. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88(12):2711-2720.
6. Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs. 2005;16(4):461-466.
7. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: results of a multi-institutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37(4):600-613.
8. Gloster HM Jr, Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35(1):82-87.
9. Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer. 2004;101(1):28-38.
10. Sawyers CL. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J Clin Oncol. 2002;20(17):3568-3569.
11. McArthur GA. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Curr Opin Oncol. 2006;18(4):341-346.
12. Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer. 2001;92(3):354-360.
13. Sjöblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 2001;61(15):5778-5783.
14. Shimizu A, O'Brien KP, Sjöblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999;59(15):3719-3723.
15. Abrams TA, Schuetze SM. Targeted therapy for dermatofibrosarcoma protuberans. Curr Oncol Rep. 2006;8(4):291-296.
16. McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol. 2004;31(2)(suppl 6):30-36.
17. McArthur GA. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease. J Natl Compr Canc Netw. 2007;5(5):557-562.
18. Mizutani K, Tamada Y, Hara K, et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol. 2004;151(1):235-237.
19. Price VE, Fletcher JA, Zielenska M, et al. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer. 2005;44(5):511-515.
20. Thomison J, McCarter M, McClain D, Golitz LE, Goldenberg G. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. J Cutan Pathol. 2008;35(11):1003-1006.
21. Gleevec (imatinib mesylate). Food and Drug Administration Web site. http://www.fda.gov/cder/drug/infopage/gleevec/default.htm. Accessed April 10, 2007.
22. Wright TI, Petersen JE. Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatol Surg. 2007;33(6):741-744.
23. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft-tissue tumors: dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet. 2003;140(1):1-12.
24. Kasper B, Lossignol D, Gil T, Flamen P, De Saint Aubain N, Awada A. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anticancer Drugs. 2006;17(10):1223-1225.
25. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 2002;100(6):623-626.
26. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002;20(17):3586-3591.
27. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23(4):866-873.
28. Savoia P, Ortoncelli M, Quaglino P, Bernengo MG. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study. Dermatol Surg. 2006;32(8):1097-1102.